Dermal fillers on FDA’s radar
This article was originally published in The Gray Sheet
Agency is putting together a "Post Market Issue Action Team" to address complaints about the long-term effects of dermal fillers, Peter Rumm, deputy director of general, restorative and neurological devices at the Office of Device Evaluation, says Sept. 17. Allergan gained expanded labeling in June for treatment effects lasting up to one year with its Juvederm Ultra and Juvederm Ultra Plus dermal fillers (1"The Gray Sheet" July 2, 2007, In Brief). BioForm Medical (Radiesse) and Artes Medical (ArteFill) are among other firms seeking longer-lasting indications
You may also be interested in...
Anti-aging dermal fillers Juvederm Ultra and Juvedermm Ultra Plus gain expanded labeling approval from FDA for treatment effects lasting up to one year - longer than any other hyaluronic acid-based filler, according to Allergan. Competing treatments include Medicis' Restylane HA-based dermal filler...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.